Glaukos (GKOS) announced the commercial availability of Epioxa HD/Epioxa, an advancement in corneal cross-linking for the treatment of keratoconus. Epioxa is now commercially available for ordering directly from Glaukos or through its specialty pharmaceutical distribution network.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Glaukos management to meet with Piper Sandler
- Glaukos Highlights Interventional Ophthalmology Strategy in Investor Update
- Glaukos Expands Eye Care Pipeline With New GLK-321 Trial in Demodex Blepharitis
- Glaukos Refines Glaucoma Implant Delivery With New Inserter Study
- AI Adoption Raises Operational, Regulatory, and Reputational Risks for Glaukos Corp.